IGFBP2 and brain neoplasm: Our current study, which focused exclusively on grade 4 diffuse gliomas, the most aggressive primary brain tumors, revealed that a nomogram based on COL22A1, IGFBP2, and MPO expression can reliably evaluate patient prognosis.